Deaths are falling, but the epidemic is becoming more complex
After years of relentless increases, new data suggests the United States may finally be seeing progress in the overdose crisis. Yet experts warn that the improvement masks a dangerous reality: the epidemic is evolving faster than the systems designed to respond to it.
According to the American Medical Association’s 2025 report on substance use and treatment, overdose deaths dropped from more than 110,000 in 2023 to roughly 75,000 in 2024.
While that decline represents thousands of lives saved, the AMA says the crisis itself is far from over.
“While the data points to meaningful progress, it also shows the overdose epidemic is evolving in dangerous ways,” said AMA President Dr. Bobby Mukkamala.
The reason: today’s overdose crisis is increasingly defined by polysubstance use, a volatile illicit drug supply and persistent barriers to treatment.
Polysubstance use is reshaping the epidemic
One of the most significant shifts in recent years is the rise of polysubstance overdoses — deaths involving multiple drugs at the same time.
The AMA report estimates that nearly 60% of overdose deaths now involve more than one substance.
In many cases, opioids like fentanyl are mixed with stimulants, sedatives or emerging substances such as xylazine. This combination dramatically increases overdose risk and complicates treatment.
Polysubstance use has been a growing challenge for addiction medicine providers. Research from The Recovery Village highlights just how common the pattern can be: its national survey of opioid users found that 89% reported using at least one additional substance alongside opioids, a behavior that significantly raises overdose risk and complicates detox and recovery.
For clinicians, this trend means treatment must address multiple substances simultaneously rather than focusing on a single drug.
Fentanyl continues to dominate the drug supply
Despite declining death totals, illicitly manufactured fentanyl remains the primary driver of overdose deaths nationwide.
Fentanyl is far more potent than heroin or prescription opioids, and it is increasingly found mixed into other drugs — sometimes without a user’s knowledge.
The AMA warns that the illicit drug supply has become “unpredictable and dangerous,” meaning even experienced users may be exposed to unexpectedly lethal doses.
This volatility is one reason why public health experts emphasize harm reduction tools like naloxone. In 2024 alone, nearly 2 million naloxone prescriptions were dispensed, reflecting expanding access through pharmacies and community organizations.
Treatment exists — but barriers remain
While overdose prevention tools are expanding, access to treatment remains uneven.
Medications for opioid use disorder (MOUD) — including buprenorphine and methadone — are widely considered the gold standard for treating opioid addiction. These medications reduce cravings, stabilize brain chemistry and significantly lower the risk of fatal overdose.
Prescriptions for buprenorphine have increased dramatically over the past decade, reflecting growing recognition of its effectiveness.
However, the AMA notes that these medications are still underused because of systemic barriers.
Common obstacles include:
Prior authorization requirements from insurers
Regulatory restrictions on methadone treatment
Stigma around addiction medications
Limited provider availability
Together, these barriers can delay or prevent patients from accessing life-saving care.
Policy changes could expand treatment access
In response to these gaps, the AMA is calling for sweeping policy changes aimed at improving treatment access.
Among the group’s top recommendations:
Eliminating prior authorization requirements for medications for opioid use disorder
Expanding methadone access beyond specialized opioid treatment programs
Strengthening enforcement of mental health and addiction treatment parity laws
Increasing community distribution of naloxone
Advocates say these reforms could help close the gap between evidence-based care and real-world treatment access.
For treatment providers, the message is clear: addiction care must become faster, more flexible and easier to access.
The human cost of delayed care
Behind the statistics are patients who often encounter delays at the very moment they are ready to seek help.
Insurance restrictions, long wait times and regulatory hurdles can push treatment days or weeks out — a window when overdose risk remains extremely high.
Behavioral health providers emphasize that substance use disorder is a medical condition requiring the same urgency as any other life-threatening illness.
From The Recovery Village’s perspective, improving access to evidence-based treatment — particularly medications for opioid use disorder — is one of the most effective ways to prevent future overdose deaths.
Addiction is treatable, but recovery often begins with removing the barriers that prevent people from entering care in the first place.
The bottom line
The recent drop in overdose deaths is encouraging, but it does not signal the end of the crisis.
Instead, experts say the epidemic is entering a new phase — one defined by polysubstance use, a dangerous drug supply and persistent gaps in treatment access.
Sustaining progress will require more than emergency responses. It will depend on whether policymakers, insurers and healthcare systems can move quickly enough to make effective addiction treatment available when people need it most.
Interview an Expert
Do you need a subject matter expert to interview on this topic? Dr. Brian D. Barash, Chief Medical Officer at The Recovery Village is available. Call us at 407-304-9824 to schedule an interview or get more information.
